Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings
- PMID: 20229272
- DOI: 10.1007/s00432-010-0846-3
Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings
Abstract
Objective: Neurofibromatosis type 1 (NF1) patients have a 13% risk of developing a malignant peripheral nerve sheath tumor (MPNST). Many MPNSTs are histopathologically complex, with regions exhibiting features of the original benign plexiform neurofibroma (PNF), of an atypical PNF, or of MPNST showing varying degrees of de-differentiation. This study analyzed the genetic alterations associated with this pathological heterogeneity in order to identify the genetic processes involved in transformation from a benign to an aggressive malignant tumor.
Methods: A histological and molecular analysis of a single MPNST tumor that was subdivided into three histopathologically distinct regions, a benign PNF (region 1), an atypical PNF (region 2), and a high-grade MPNST (region 3), was carried out. Tumor DNA from each region was analyzed in conjunction with the patient's lymphocyte DNA. Somatic mutation analyses included loss-of heterozygosity (LOH), MLPA analysis, NF1 gene sequencing, and a microarray comparative genomic hybridisation (array CGH) analysis.
Results: The patient had a germline NF1 splice-site mutation. The NF1-associated LOH analysis found that LOH increased in the three tumor areas, with 9, 42, and 97% LOH evident in regions 1, 2, and 3, respectively. Additional genetic changes, including losses of TP53, RB1, CDKN2A, and of several oncogenes and cell-cycle genes, were found only in the malignant MPNST (region 3). Array CGH also identified genomic gains and losses in DNA from region 3.
Discussion: This is the first study that correlates the histological and molecular changes associated with MPNST development, confirming the significant cellular and genetic heterogeneity that poses both diagnostic and therapeutic challenges.
Similar articles
-
Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.Anticancer Res. 2009 Apr;29(4):1255-62. Anticancer Res. 2009. PMID: 19414372
-
Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32. doi: 10.1002/gcc.20921. Epub 2011 Aug 24. Genes Chromosomes Cancer. 2011. PMID: 21987445
-
Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.Hum Mutat. 2004 Feb;23(2):134-146. doi: 10.1002/humu.10305. Hum Mutat. 2004. PMID: 14722917
-
Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors.Front Biosci (Landmark Ed). 2011 Jan 1;16(3):937-51. doi: 10.2741/3727. Front Biosci (Landmark Ed). 2011. PMID: 21196210 Review.
-
Malignant Peripheral Nerve Sheath Tumor.Surg Oncol Clin N Am. 2016 Oct;25(4):789-802. doi: 10.1016/j.soc.2016.05.009. Surg Oncol Clin N Am. 2016. PMID: 27591499 Review.
Cited by
-
Comparison of hybrid 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1.World J Nucl Med. 2018 Oct-Dec;17(4):241-248. doi: 10.4103/wjnm.WJNM_71_17. World J Nucl Med. 2018. PMID: 30505221 Free PMC article.
-
Perinatal folate levels do not influence tumor latency or multiplicity in a model of NF1 associated plexiform-like neurofibromas.BMC Res Notes. 2023 Oct 17;16(1):275. doi: 10.1186/s13104-023-06515-8. BMC Res Notes. 2023. PMID: 37848948 Free PMC article.
-
Monozygotic twins with Neurofibromatosis type 1, concordant phenotype and synchronous development of MPNST and metastasis.BMC Cancer. 2010 Aug 5;10:407. doi: 10.1186/1471-2407-10-407. BMC Cancer. 2010. PMID: 20687928 Free PMC article.
-
Wilms' tumor gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line.PLoS One. 2014 Dec 4;9(12):e114333. doi: 10.1371/journal.pone.0114333. eCollection 2014. PLoS One. 2014. PMID: 25474318 Free PMC article.
-
A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis.Neuro Oncol. 2021 Apr 12;23(4):557-571. doi: 10.1093/neuonc/noaa280. Neuro Oncol. 2021. PMID: 33326583 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous